A Phase 2a Efficacy, Safety, Tolerability, and PK Study of Encochleated Amphotericin B (CAMB/MAT2203) in Patients With Mucocutaneous Candidiasis Who Are Refractory or Intolerant to Standard Non-Intravenous Therapies

Trial Profile

A Phase 2a Efficacy, Safety, Tolerability, and PK Study of Encochleated Amphotericin B (CAMB/MAT2203) in Patients With Mucocutaneous Candidiasis Who Are Refractory or Intolerant to Standard Non-Intravenous Therapies

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs Amphotericin B (Primary)
  • Indications Mucocutaneous candidiasis
  • Focus Therapeutic Use
  • Acronyms CAMB
  • Sponsors Aquarius Biotechnologies; Matinas BioPharma
  • Most Recent Events

    • 08 Jan 2018 According to a Matinas BioPharma media release, the Institutional Review Board of the NIAID, NIH has granted approval for two separate 6-month open-label safety extensions of this Phase 2a study to allow patients to continue to receive MAT2203.
    • 08 Jan 2018 Primary endpoint (Symptoms of mucocutaneous candidiasis) has been met, according to a Matinas BioPharma media release.
    • 08 Jan 2018 Data from third patient enrolled in the study presented in a Matinas BioPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top